en · de · es · fr · pt
tb-500-notes.peptides9002.com › Topic › Tb-500 Identity And Naming Background — Background and Details

Tb-500 Identity And Naming Background — Background and Details

By Editorial Desk · published 2026-06-06 · last reviewed 2026-07-05 · Topic

Everything below concerns Ac-LKKTETQ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Identity and Research Background

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

Related pages on this site

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Notes from published material

=== Consumer use as normal === Some consumers can face the difficult position of being unable to afford their medication, and choosing between using expired medication or forgoing medication. An epipen is an example of an expensive medication which someone might consider using after expiration because of inability to purchase newer medication. Some common drugs which authorities say are always unsafe if expired include nitroglycerin, insulin, and liquid antibiotics. Consumers sometimes store drugs which they ought not use, regardless of being expired. People who have leftover antibiotics might feel that they can use them safely if they are not expired, or even if they are expired. Medical authorities recommend that no one use prescription drugs except under a physician's care. Authorities also encourage care in storing over-the-counter drugs, discarding them on a regular schedule, and using them as directed when appropriate.

Evaporative and other processes in bodies of water, and also ground water processes, also differentially alter the ratios of heavy hydrogen and oxygen isotopes in fresh and salt waters, in characteristic and often regionally distinctive ways. The ratio of concentration of 2H to 1H is usually indicated with a delta as δ2H and the geographic patterns of these values are plotted in maps termed as isoscapes. Stable isotopes are incorporated into plants and animals and an analysis of the ratios in a migrant bird or insect can help suggest a rough guide to their origins.

== History == Congebec was founded in 1974 by Laurier Pedneault following the acquisition of a warehouse on Dalhousie street, near Quebec City's old port. In 1997 Congebec purchased its first warehouse in the Montreal region. In 2002, it was the first phase of construction for the Boucherville warehouse which was the beginning of a strong expansion for Congebec. In 2004, Congebec purchased the Centre Frigorifique Montérégie, which is now referred to as Sainte-Julie warehouse. In doing so, Congebec also purchased CFM logistics that now is Congebec's transport division. After the acquisition, Congebec became the largest refrigerated warehouse company in Quebec and second largest in Canada. In 2006, the Boucherville warehouse was considerably expanded. A seventh warehouse was built in Manseau in autumn 2008. This warehouse is almost entirely dedicated to the cranberry industry. In 2011, Congebec entered the Toronto market with the opening of an 8th refrigerated warehouse strategically located near Pearson Airport, with more than three million cubic feet. In 2013, Congebec conducted its largest expansion in history by acquiring four Westco Multitemp warehouses located in Calgary, Saskatoon and Winnipeg, which gave Congebec a total of more than 48.3 million cubic feet. In 2015, Capital régional et coopératif Desjardins (CRCD), a retail fund managed by Canadian private equity firm Desjardins Capital de risque, led an undisclosed investment in Congebec Logistic Inc.

Mirroring the upwards trend in the volume of opioid pain relievers prescribed was an increase in admissions for substance use disorder treatments and opioid-related deaths. This illustrates how legitimate clinical prescriptions of pain relievers were being diverted through an illegitimate market, leading to misuse, addiction, and death. With the increase in volume, the potency of opioids also increased. By 2002, one in six opioid users was prescribed drugs more powerful than morphine. By 2012, the ratio had doubled to one in three. The most commonly prescribed opioids were oxycodone and hydrocodone.

Sources: en.wikipedia.org

Background from the literature

An intermediate bulk container (IBC, IBC Tote, IBC Tank) is a multi-use container employed for the general transport, storage, and handling of bulk fluids and materials. IBC tanks are compatible with, and resistant to, an extensive list of chemicals, acids, caustics, as well as inert materials and food grade consumables. IBCs are commonly manufactured from the following materials:

Subsequently, the juice production creates a significant additional financial gain without compromising the fiber production in any way. In climate zones in which hemp seeds do not ripen easily such as Northern Europe, the juice production represents and additional utilization of the hemp plant. Additionally to hemp juice, press remnants of approximately 3 tons per ha are being gained. A quarter to a third of the ingredients found in hemp juice are present in the press remnants. These constitute a valuable food part for humans as well for instance used to bake bread. They also can be dried or fermented and used as cattle feed. On top of this, cold-pressing the fibers and shives offers an additional added value of the plant. It is also possible with a suitable pressing procedure during harvest to press the juice of the entire hemp plant. The use of the fiber in industry is not necessarily compromised if the right pressing process is chosen. The resulting juice of the hemp stem represents an additional value added. It can be used for bio-gas production of energy or in fermenting lactic acid for the chemical industry. Cold-pressing the fibers and shives does not compromise their value for further industrial processing.

A caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia. As the risk of developing type 2 diabetes is about 10 times higher in women with a history of gestational diabetes, postpartum screening may involve dietary, lifestyle, and drug interventions to prevent or delay its progression.

Sources: en.wikipedia.org

Further detail

== Use during the 2018-19 Kivu Ebola outbreak in the Democratic Republic of the Congo == The ZMapp cocktail was assessed by the World Health Organization for emergency use under the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) ethical protocol. The panel agreed that "the benefits of ZMapp outweigh its risks" while noting that it presented logistical challenges, particularly that of requiring a cold chain for distribution and storage. Four alternative therapies (remdesivir, the Regeneron product atoltivimab/maftivimab/odesivimab, favipiravir, and ansuvimab) were also considered for use, but they were at earlier stages of development. In August 2019, the Democratic Republic of the Congo's national health authorities, the World Health Organization, and the National Institutes of Health announced that they would stop using ZMapp, along with all other Ebola treatments except atoltivimab/maftivimab/odesivimab and ansuvimab, in their ongoing clinical trials, citing the higher mortality rates of patients not treated with atoltivimab/maftivimab/odesivimab and ansuvimab. In October 2020, the US Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab with an indication for the treatment of infection caused by Zaire ebolavirus.

== Types == Pumps can be broadly categorized according to three techniques: positive displacement, momentum transfer, and entrapment. Positive displacement pumps use a mechanism to repeatedly expand a cavity, allow gases to flow in from the chamber, seal off the cavity, and exhaust it to the atmosphere. Momentum transfer pumps, also called molecular pumps, use high-speed jets of dense fluid or high-speed rotating blades to knock gas molecules out of the chamber. Entrapment pumps capture gases in a solid or adsorbed state; this includes cryopumps, getters, and ion pumps. Positive displacement pumps are the most effective for low vacuums. Momentum transfer pumps, in conjunction with one or two positive displacement pumps, are the most common configuration used to achieve high vacuums. In this configuration the positive displacement pump serves two purposes. First, it obtains a rough vacuum in the vessel being evacuated before the momentum transfer pump can be used to obtain the high vacuum, as momentum transfer pumps cannot start pumping at atmospheric pressures. Second, the positive displacement pump backs up the momentum transfer pump by evacuating to low vacuum the accumulation of displaced molecules in the high vacuum pump. Entrapment pumps can be added to reach ultrahigh vacuums, but they require periodic regeneration of the surfaces that trap air molecules or ions. Due to this requirement their available operational time can be unacceptably short in low and high vacuums, thus limiting their use to ultrahigh vacuums.

=== Insulinoma === Insulinoma is a rare tumor derived from the neoplasia of beta cells. Insulinomas are usually benign, but may be medically significant and even life-threatening due to recurrent and prolonged attacks of hypoglycemia.

Some Prefer Nettles (蓼喰う虫, Tade kū mushi; Historical orthography: 蓼喰ふ蟲) is a 1929 novel by Jun'ichirō Tanizaki. It was first published in 1928–9 as a newspaper serial. The novel is often regarded as the most autobiographical of Tanizaki's works and one of his finest novels. The Japanese title of the novel is literally water pepper-eating bugs, and is the first half of the Japanese saying tade kuu mushi mo sukizuki (蓼食う虫も好き好き), or "Water pepper-eating bugs eat it willingly", equivalent to the English "To each his own." The translation as Some Prefer Nettles was chosen by Edward Seidensticker. He considered it one of his most noted translations, and it has been included as a translation of the original saying in the authoritative Kenkyūsha's New Japanese-English Dictionary.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Network